Sugi Predict

Sugi Predict / Compounds / SCHEMBL2023907

SCHEMBL2023907

SCHEMBL2023907

Cc1cc(CN(C)CC2CCNCC2)cc2c1C(=O)N(Cc1ccc(OC(F)(F)F)cc1)C2

nearest known ligand 0.53

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ GRM2 Q14416 3/20 0.53
▸ HTR2C P28335 2/20 0.39
▸ HCRTR1 O43613 9/20 0.36
▸ HCRTR2 O43614 9/20 0.36
▸ PSEN1 P49768 1/20 0.35
▸ PSEN2 P49810 1/20 0.35
▸ APH1B Q8WW43 1/20 0.35
▸ NCSTN Q92542 1/20 0.35
▸ APH1A Q96BI3 1/20 0.35
▸ PSENEN Q9NZ42 1/20 0.35
▸ GRIN2B Q13224 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ LSS P48449 1/20 0.33
▸ CHRM5 P08912 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2027205 0.91 GRM2 (0.48) GRM2HCRTR1HCRTR2GRIN2BALDH1A1
SCHEMBL2026779 0.89 GRM2 (0.57) GRM2HTR2CHCRTR1HCRTR2GRIN2B
SCHEMBL12442033 0.88 GRM2 (0.53) GRM2HTR2CHCRTR1HCRTR2PSEN1
SCHEMBL12580820 0.88 GRM2 (0.56) GRM2HTR2CHCRTR1HCRTR2GRIN2B
SCHEMBL2023985 0.86 GRM2 (0.54) GRM2HTR2CHCRTR1HCRTR2GRIN2B
SCHEMBL2027206 0.86 GRM2 (0.51) GRM2HTR2CHCRTR1HCRTR2PSEN1
SCHEMBL2022914 0.85 GRM2 (0.53) GRM2HTR2CHCRTR1HCRTR2GRIN2B
SCHEMBL2025995 0.83 GRM2 (0.55) GRM2HTR2CHCRTR1HCRTR2GRIN2B
SCHEMBL2022432 0.83 GRM2 (0.50) GRM2HCRTR1HCRTR2GRIN2BALDH1A1
SCHEMBL2023969 0.82 GRM2 (0.57) GRM2HTR2CHCRTR1HCRTR2GRIN2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2357169-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators AstraZeneca AB (SE) 2011-08-17 — — EP disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 — — US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 — — US disclosed
US-7968570-B2 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2011-06-28 — — US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 — — US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 — — US disclosed
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators ASTRAZENECA AB (SE) 2009-11-05 — — US disclosed
WO-2006020879-A1 ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS ASTRAZENECA AB (SE) 2006-02-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275578-A1 Isoindolone compounds and their use as metabotropic glutamate receptor potentiators GRM1, GRIN1, GRM3 GRM2 4/4885HTR2C 616/4885HCRTR1 260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.